NASDAQ:FBIO Fortress Biotech (FBIO) Stock Price, News & Analysis → Central Bank Gold Heist In Progress (From Colonial Metals) (Ad) Free FBIO Stock Alerts $1.92 -0.02 (-1.03%) (As of 03/18/2024 ET) Add Compare Share Share Today's Range$1.79▼$2.0050-Day Range$1.68▼$2.4352-Week Range$1.24▼$12.75Volume339,104 shsAverage Volume470,204 shsMarket Capitalization$17.16 millionP/E RatioN/ADividend YieldN/APrice Target$53.33 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Fortress Biotech alerts: Email Address Fortress Biotech MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside2,677.8% Upside$53.33 Price TargetShort InterestHealthy11.54% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.56Based on 8 Articles This WeekInsider TradingAcquiring Shares$119,000 Bought Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.27 out of 5 starsMedical Sector353rd out of 947 stocksPharmaceutical Preparations Industry166th out of 435 stocks 3.5 Analyst's Opinion Consensus RatingFortress Biotech has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $53.33, Fortress Biotech has a forecasted upside of 2,677.8% from its current price of $1.92.Amount of Analyst CoverageFortress Biotech has only been the subject of 1 research reports in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted11.54% of the float of Fortress Biotech has been sold short.Short Interest Ratio / Days to CoverFortress Biotech has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Fortress Biotech has recently decreased by 6.10%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldFortress Biotech does not currently pay a dividend.Dividend GrowthFortress Biotech does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for FBIO. Previous Next 2.5 News and Social Media Coverage News SentimentFortress Biotech has a news sentiment score of 0.56. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Fortress Biotech this week, compared to 1 article on an average week.Search Interest13 people have searched for FBIO on MarketBeat in the last 30 days. This is an increase of 30% compared to the previous 30 days.MarketBeat FollowsOnly 25 people have added Fortress Biotech to their MarketBeat watchlist in the last 30 days. This is a decrease of -4% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Fortress Biotech insiders have bought more of their company's stock than they have sold. Specifically, they have bought $119,000.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders26.90% of the stock of Fortress Biotech is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 18.15% of the stock of Fortress Biotech is held by institutions. Previous Next 0.6 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Fortress Biotech is -0.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Fortress Biotech is -0.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioFortress Biotech has a P/B Ratio of 0.28. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Prosper Trading AcademyDid you make $29,000 two days with AI options trades?What if it was possible to find options trades on autopilot… Using A.I. to find the ones with the highest profit potential… And nearly perfect win rates… You can grab your free copy of my "Ultimate Guide to A.I. Options Trading" by clicking the link below:Click Here To Get Your Free Copy About Fortress Biotech Stock (NASDAQ:FBIO)Fortress Biotech, Inc., a biopharmaceutical company, develops and commercializes pharmaceutical and biotechnology products. The company markets dermatology products, such as Ximino an oral minocycline drug for the treatment of moderate to severe acne; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Exelderm cream for antifungal intended for topical use; Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Amzeeq; Zilxi; and Accutane capsules for severe recalcitrant nodular acne. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; MB-107 and MB-207 for the treatment of X-linked severe combined immunodeficiency; Cosibelimab for metastatic cancers; CK-101 for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and CEVA101 for the treatment of severe traumatic brain injury in adults and children. The company's early stage product candidates include MB-102 for blastic plasmacytoid dendritic cell neoplasm; MB-101 for glioblastoma; MB-104 for multiple myeloma and light chain amyloidosis; MB-106 for B-cell non-hodgkin lymphoma; MB-103 for GBM & metastatic breast cancer to brain; MB-108; MB-105 for prostate and pancreatic cancers; and BAER-101. Its preclinical product candidates comprise AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; and ONCOlogues, and oligonucleotide platform. It has collaboration arrangements with universities, research institutes, and pharmaceutical companies. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida.Read More FBIO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart FBIO Stock News HeadlinesMarch 18, 2024 | finance.yahoo.comAvenue Therapeutics Reports Full Year 2023 Financial Results and Recent Corporate HighlightsMarch 18, 2024 | globenewswire.comJourney Medical Corporation Announces U.S. FDA Acceptance of New Drug Application for DFD-29 for the Treatment of RosaceaMarch 19, 2024 | Crypto 101 Media (Ad)Altcoin FRENZY Alert…Bitcoin recently crossed the highest price in its 15-year history… Less than 2 years after one of the most vicious crypto market meltdowns we've ever seen! Bitcoin's BOOM also sent shockwaves through the altcoin market, with select coins seeing HUGE moves in a matter of days… Like Fetch.ai, that gained over 350% in just the last 30 days… March 16, 2024 | americanbankingnews.comFortress Biotech (NASDAQ:FBIO) Now Covered by Analysts at Roth MkmMarch 15, 2024 | globenewswire.comJourney Medical Corporation to Announce Year End 2023 Financial Results on March 21, 2024March 13, 2024 | globenewswire.comJourney Medical Corporation to Participate in the 36th Annual ROTH ConferenceMarch 12, 2024 | globenewswire.comFortress Biotech to Participate in 36th Annual ROTH ConferenceMarch 11, 2024 | globenewswire.comJourney Medical Corporation Announces Presentation of Data from Phase 1 Clinical Trial Assessing the Impact of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) on Microbial Flora of Healthy Adults at 2024 AAD Annual MeetingMarch 19, 2024 | The Bull Report (Ad)The AI Bottleneck No One is Talking AboutRenewable energy is growing at an impressive speed - but not fast enough. This could be one of the greatest periods for the nuclear industry ever.March 4, 2024 | globenewswire.comFortress Biotech and Cyprium Therapeutics Announce $4.1 Million Grant from NINDS to Further Development of AAV-ATP7A Gene Therapy for Menkes DiseaseJanuary 29, 2024 | finance.yahoo.comCheckpoint Therapeutics Announces $14 Million Registered Direct Offering Priced At-the-MarketJanuary 11, 2024 | finance.yahoo.comAvenue Therapeutics to Present at Sidoti January Micro-Cap Investor ConferenceJanuary 9, 2024 | finance.yahoo.comInsider Buying: President, CEO & Chairman, 10% Owner ROSENWALD LINDSAY A MD Acquires 50,000 ...January 5, 2024 | finance.yahoo.comJourney Medical Corporation Submits New Drug Application to FDA for DFD-29 to Treat RosaceaJanuary 5, 2024 | finance.yahoo.comAvenue Therapeutics Enters into Warrant Exercise Transactions for $5.0 Million in ProceedsJanuary 4, 2024 | finance.yahoo.comAvenue Therapeutics Reaches Final Agreement with the U.S. FDA for the Phase 3 Safety Study for IV TramadolJanuary 2, 2024 | finance.yahoo.comAvenue Therapeutics Announces Completion of Enrollment in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)December 29, 2023 | markets.businessinsider.comWhy Fortress Biotech Shares Are Tumbling TodayDecember 11, 2023 | finance.yahoo.comMustang Bio Presents Updated Phase 1/2 Multicenter Clinical Data for MB-106 at the 2023 American Society of Hematology (ASH) Annual MeetingDecember 6, 2023 | finance.yahoo.comJourney Medical Corporation Announces Successful Completion of Pre-NDA Meeting with the FDA for DFD-29 to Treat RosaceaDecember 6, 2023 | finance.yahoo.comSentynl Therapeutics Completes Asset Transfer of CUTX-101 Copper Histidinate Product Candidate for Treatment of Menkes Disease from Cyprium TherapeuticsDecember 6, 2023 | finance.yahoo.comCyprium Therapeutics, a Fortress Biotech Subsidiary Company, Completes Asset Transfer of CUTX-101 Copper Histidinate Product Candidate for Treatment of Menkes Disease, to Sentynl Therapeutics, a Wholly-owned Subsidiary of Zydus Lifesciences Ltd.December 1, 2023 | benzinga.comFortress Biotech Stock (NASDAQ:FBIO), Analyst Ratings, Price Targets, PredictionsDecember 1, 2023 | finance.yahoo.comAvenue Therapeutics to Present at American Epilepsy Society 2023 Annual MeetingNovember 29, 2023 | markets.businessinsider.comRoth MKM Maintains Buy Rating for Fortress Biotech: Here's What You Need To KnowNovember 17, 2023 | benzinga.comThinking about buying stock in Coinbase Global, Celsius Holdings, Cadence Design Systems, Coherus Biosciences, or Fortress Biotech?November 13, 2023 | finance.yahoo.comCheckpoint Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate HighlightsSee More Headlines Receive FBIO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Fortress Biotech and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/15/2021Today3/19/2024Next Earnings (Estimated)4/04/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:FBIO CUSIP21976U10 CIK1429260 Webwww.fortressbiotech.com Phone(781) 652-4500Fax781-652-4545Employees187Year FoundedN/APrice Target and Rating Average Stock Price Target$53.33 High Stock Price Target$75.00 Low Stock Price Target$10.00 Potential Upside/Downside+2,677.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($12.1844) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-86,570,000.00 Net Margins-96.71% Pretax Margin-224.80% Return on Equity-770.86% Return on Assets-35.23% Debt Debt-to-Equity RatioN/A Current Ratio1.00 Quick Ratio0.89 Sales & Book Value Annual Sales$75.74 million Price / Sales0.23 Cash FlowN/A Price / Cash FlowN/A Book Value$6.79 per share Price / Book0.28Miscellaneous Outstanding Shares8,940,000Free Float6,537,000Market Cap$17.16 million OptionableOptionable Beta1.52 The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesDr. Lindsay Allan Rosenwald (Age 69)Executive Chairman, President & CEO Comp: $942.78kMr. Michael S. Weiss Esq. (Age 58)Vice Chairman & Executive Vice Chairman of Strategic Development Comp: $167.92kMr. David Jin (Age 33)CFO & Head of Corporate Development Comp: $976.96kDr. George C. Avgerinos (Age 70)Senior Vice President of Biologics Operations Comp: $386.49kMr. Samuel BerryGeneral Counsel & Corporate SecretaryKey CompetitorsMolecular TemplatesNASDAQ:MTEMRegulus TherapeuticsNASDAQ:RGLSBolt BiotherapeuticsNASDAQ:BOLTSynlogicNASDAQ:SYBXAgeX TherapeuticsNYSE:AGEView All CompetitorsInsiders & InstitutionsB. Riley Wealth Advisors Inc.Sold 58,725 shares on 3/15/2024Ownership: 0.962%PVG Asset Management CorpBought 131,490 shares on 3/12/2024Ownership: 1.471%Vanguard Group Inc.Sold 4,904,662 shares on 3/11/2024Ownership: 3.959%Goldman Sachs Group Inc.Sold 152,661 shares on 3/1/2024Ownership: 0.121%Citadel Advisors LLCBought 12,700 shares on 2/15/2024Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions FBIO Stock Analysis - Frequently Asked Questions Should I buy or sell Fortress Biotech stock right now? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Fortress Biotech in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" FBIO shares. View FBIO analyst ratings or view top-rated stocks. What is Fortress Biotech's stock price target for 2024? 4 brokerages have issued twelve-month target prices for Fortress Biotech's shares. Their FBIO share price targets range from $10.00 to $75.00. On average, they expect the company's stock price to reach $53.33 in the next year. This suggests a possible upside of 2,677.8% from the stock's current price. View analysts price targets for FBIO or view top-rated stocks among Wall Street analysts. How have FBIO shares performed in 2024? Fortress Biotech's stock was trading at $3.01 at the start of the year. Since then, FBIO stock has decreased by 36.2% and is now trading at $1.92. View the best growth stocks for 2024 here. Are investors shorting Fortress Biotech? Fortress Biotech saw a decrease in short interest during the month of February. As of February 29th, there was short interest totaling 1,540,000 shares, a decrease of 6.1% from the February 14th total of 1,640,000 shares. Based on an average daily trading volume, of 550,700 shares, the days-to-cover ratio is currently 2.8 days. Approximately 11.5% of the company's shares are short sold. View Fortress Biotech's Short Interest. When is Fortress Biotech's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, April 4th 2024. View our FBIO earnings forecast. How were Fortress Biotech's earnings last quarter? Fortress Biotech, Inc. (NASDAQ:FBIO) released its quarterly earnings results on Monday, November, 15th. The biopharmaceutical company reported ($2.10) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.20) by $0.90. The biopharmaceutical company earned $21.09 million during the quarter, compared to the consensus estimate of $18.41 million. Fortress Biotech had a negative trailing twelve-month return on equity of 770.86% and a negative net margin of 96.71%. When did Fortress Biotech's stock split? Fortress Biotech shares reverse split on the morning of Tuesday, October 10th 2023. The 1-15 reverse split was announced on Monday, October 9th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, October 9th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. What other stocks do shareholders of Fortress Biotech own? Based on aggregate information from My MarketBeat watchlists, some companies that other Fortress Biotech investors own include Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Novavax (NVAX), Advanced Micro Devices (AMD), OPKO Health (OPK), TG Therapeutics (TGTX), Vaxart (VXRT), NVIDIA (NVDA), Pfizer (PFE) and Dynavax Technologies (DVAX). Who are Fortress Biotech's major shareholders? Fortress Biotech's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Armistice Capital LLC (6.67%), Nantahala Capital Management LLC (4.17%), Vanguard Group Inc. (3.96%), Vanguard Group Inc. (3.96%), Shikiar Asset Management Inc. (2.05%) and PVG Asset Management Corp (1.47%). Insiders that own company stock include Lindsay A Md Rosenwald and Michael S Weiss. View institutional ownership trends. How do I buy shares of Fortress Biotech? Shares of FBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:FBIO) was last updated on 3/19/2024 by MarketBeat.com Staff From Our PartnersCentral Bank Gold Heist In ProgressColonial Metals8,788% Return Predicted For THIS Crypto (already up 40% in 6 months)Paradigm PressAltcoin FRENZY Alert…Crypto 101 MediaThe AI Bottleneck No One is Talking AboutThe Bull ReportMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceSHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyThe world’s greatest investmentPorter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Fortress Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.